Astrid C Erber1,2, Hakan Cetin3, David Berry4,5, Eva S Schernhammer1,6. 1. Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria. 2. Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Headington, Oxford, UK. 3. Department of Neurology, Medical University of Vienna, Vienna, Austria. 4. Division of Microbial Ecology, Department of Microbiology and Ecosystem Function, Centre for Microbiology and Environmental Systems Science, University of Vienna, Vienna, Austria. 5. Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria. 6. Channing Division of Network Medicine, Harvard Medical School, Boston, MA, USA.
Abstract
Aim of the study: We conducted a systematic review on existing literature in humans and animals, linking the gut microbiome with amyotrophic lateral sclerosis (ALS). Additionally, we sought to explore the role of the bacterially produced metabolite butyrate as well as of proton pump inhibitors (PPIs) in these associations.Materials and methods: Following PRISMA guidelines for systematic literature reviews, four databases (Medline, Scopus, Embase and Web of Science) were searched and screened by two independent reviewers against defined inclusion criteria. Six studies in humans and six animal studies were identified, summarized and reviewed. Results: Overall, the evidence accrued to date is supportive of changes in the gut microbiome being associated with ALS risk, and potentially progression, though observational studies are small (describing a total of 145 patients with ALS across all published studies), and not entirely conclusive.Conclusions: With emerging studies beginning to apply metagenome sequencing, more clarity regarding the importance and promise of the gut microbiome in ALS can be expected. Future studies may also help establish the therapeutic potential of butyrate, and the role of PPIs in these associations.
Aim of the study: We conducted a systematic review on existing literature in humans and animals, linking the gut microbiome with amyotrophic lateral sclerosis (ALS). Additionally, we sought to explore the role of the bacterially produced metabolite butyrate as well as of proton pump inhibitors (PPIs) in these associations.Materials and methods: Following PRISMA guidelines for systematic literature reviews, four databases (Medline, Scopus, Embase and Web of Science) were searched and screened by two independent reviewers against defined inclusion criteria. Six studies in humans and six animal studies were identified, summarized and reviewed. Results: Overall, the evidence accrued to date is supportive of changes in the gut microbiome being associated with ALS risk, and potentially progression, though observational studies are small (describing a total of 145 patients with ALS across all published studies), and not entirely conclusive.Conclusions: With emerging studies beginning to apply metagenome sequencing, more clarity regarding the importance and promise of the gut microbiome in ALS can be expected. Future studies may also help establish the therapeutic potential of butyrate, and the role of PPIs in these associations.
Entities:
Keywords:
ALS; Microbiome; butyrate; gut microbiota; proton pump inhibitors
Authors: B Kuraszkiewicz; H Goszczyńska; T Podsiadły-Marczykowska; M Piotrkiewicz; P Andersen; M Gromicho; J Grosskreutz; M Kuźma-Kozakiewicz; S Petri; B Stubbendorf; K Szacka; H Uysal; M de Carvalho Journal: Front Neurosci Date: 2020-05-26 Impact factor: 4.677
Authors: Hugo Alarcan; Romane Chaumond; Patrick Emond; Isabelle Benz-De Bretagne; Antoine Lefèvre; Salah-Eddine Bakkouche; Charlotte Veyrat-Durebex; Patrick Vourc'h; Christian Andres; Philippe Corcia; Hélène Blasco Journal: Biomolecules Date: 2021-05-05